Printer Friendly

PHARMACEUTICAL RESOURCES REPORTS THIRD QUARTER PROFIT ON 62 PERCENT INCREASE IN SALES

 PHARMACEUTICAL RESOURCES REPORTS THIRD QUARTER PROFIT
 ON 62 PERCENT INCREASE IN SALES
 SPRING VALLEY, N.Y., Aug. 6 /PRNewswire/ -- Pharmaceutical Resources, Inc. (NYSE, PSE: PRX) today reported a profit for its fiscal quarter ended June 27, 1992, on a sales increase of 62 percent over the prior year.
 Net sales from continuing operations for the quarter were $13,507,000, a 62 percent increase over the net sales of $8,317,000 from continuing operations for the third quarter of fiscal 1991. Net income for the quarter was $1,857,000, or $.12 per share, as compared with a net loss of $3,122,000, or $.27 per share, a year earlier. Income from continuing operations was $1,207,000 ($.08 per share) as compared with a loss from continuing operations of $628,000 ($.06 per share) a year earlier. The net income for the current quarter includes the benefit of an extraordinary tax credit of $650,000 ($.04 per share). The net loss for 1991s third quarter included a loss from discontinued operations (representing the operations of the company's Quad Pharmaceuticals subsidiary) of $2,494,000 ($.21 per share).
 For the nine months ended June 27, 1992, the company recorded net income of $3,417,000, or $.23 per share, on net sales from continuing operations of $37,717,000, compared to a net loss of $13,107,000, or $1.13 per share, on net sales of $24,345,000 for the corresponding nine months of fiscal 1991. Net income in the current nine month period includes the benefit of an extraordinary tax credit of $1,200,000 ($.08 per share). The net loss for the nine months ended June 29, 1991 included a loss from discontinued operations of $10,014,000 ($.86 per share).
 Kenneth I. Sawyer, president of Pharmaceutical Resources, said that the sales growth of the company continues to reflect increased market penetration of the company's oral solid product line. Sawyer said, "the increasing acceptance of our product line is the direct result of the extensive rebuilding of the company that we have successfully accomplished over the past three years. This has been manifested not only by customer acceptance, but also by the amicable resolution, before and during the past quarter, of issues with both federal and state governments. We now are turning our concerted efforts to the company's future growth and success. Our sales orders continue to be strong, and we have achieved desired increases in manufacturing throughput. We look forward to continued progress."
 Pharmaceutical Resources, Inc. is the parent company of Par Pharmaceutical, Inc., a manufacturer and marketer of prescription and over-the-counter generic drugs.
 PHARMACEUTICAL RESOURCES, INC.
 Third quarter 6/27/92 6/29/91(A)
 Net sales from continuing operations $13,507,000 $ 8,317,000
 Income (loss) from continuing operations 1,207,000 (628,000)
 (Loss) from discontinued operations (A) -- (2,494,000)
 Income (loss) before extraordinary credit 1,207,000 (3,122,000)
 Extraordinary credit (B) 650,000 --
 Net income (loss) 1,857,000 (3,122,000)
 Earnings (loss) per share:
 Continuing operations .08 (.06)
 Discontinued operations (A) -- (.21)
 Extraordinary credit (B) .04 --
 Net income (loss) .12 (.27)
 Average shares and equivalents (C) 14,927,000 11,668,000
 Nine months 6/27/92 6/29/91(A)
 Net sales from continuing operations $37,717,000 $24,345,000
 Income (loss) from continuing operations 2,217,000 (3,093,000)
 (Loss) from discontinued operations (A) -- (10,014,000)
 Income (loss) before extraordinary credit 2,217,000 (13,107,000)
 Extraordinary credit (B) 1,200,000 --
 Net income (loss) 3,417,000 (13,107,000)
 Earnings (loss) per share:
 Continuing operations .15 (.27)
 Discontinued operations (A) -- (.86)
 Extraordinary credit (B) .08 --
 Net income (loss) .23 (1.13)
 Average shares and equivalents (C) 14,778,000 11,636,000
 (A) In September 1991, the company made a decision to discontinue the operations of its Quad Pharmaceuticals subsidiary. Results of operations for 1991 have been reclassified to state separately the results of the discontinued operations.
 (B) Tax benefit of utilization of net operating loss carryforward.
 (C) Includes, in 1992, 515,000 common shares and 2 million preferred shares to be issued in connection with settlement of litigation.
 -0- 8/6/92
 /CONTACT: Richard J. Nadler or Richard J. Strobel of Pharmaceutical Resources, 914-425-7100/
 (PRX) CO: Pharmaceutical Resources, Inc. ST: New York IN: MTC SU: ERN


PS-OS -- NY048 -- 7568 08/06/92 11:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1992
Words:741
Previous Article:CALIFORNIA'S LARGEST HOME BUILDER PUTTING DOWN ROOTS IN FRESNO MARKET
Next Article:PENNSYLVANIA TURNPIKE COMMISSION ANNOUNCES LANE CLOSURES
Topics:


Related Articles
SPI PHARMACEUTICALS REPORTS RECORD SECOND QUARTER SALES AND NET INCOME
SPI PHARMACEUTICALS INC. REPORTS THIRD QUARTER NET INCOME INCREASE
SPI PHARMACEUTICALS INC. REPORTS THIRD QUARTER NET INCOME INCREASE
ICN PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
ICN PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS /repeating from earlier today/
SPI PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS; EARNINGS UP 37 PERCENT IN U.S., LATIN AMERICA AND WESTERN EUROPE
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES RECORD SALES AND PROFITS
SMITHKLINE BEECHAM ANNOUNCES THIRD-QUARTER 1994 RESULTS: SALES INCREASE 8 PERCENT; EARNINGS PER SHARE UP 4 PERCENT; NEW PHARMACEUTICAL PRODUCTS SALES...
ICN PHARMACEUTICALS REPORTS RECORD SALES, NET INCOME AND EARNINGS PER SHARE IN THIRD QUARTER
Schering-Plough Reports Sales, Earnings for 2001 Third Quarter, First Nine Months.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters